



# INFLAMMATORY BOWEL DISEASE SPECIALTY CARE PROGRAM

## Phone: 617-254-5900

### 1 PATIENT INFORMATION:

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
 Email: \_\_\_\_\_  
 DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
 Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

### 2 PRESCRIBER INFORMATION:

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
 Tax I.D.: \_\_\_\_\_  
 Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

### 3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: \_\_\_\_\_  
 Crohn's Disease  Ulcerative Colitis  Irritable Bowel Syndrome  
 ICD-10: \_\_\_\_\_  
 Other: \_\_\_\_\_  
 Serious or active infection present?  Yes  No  
 Hep B ruled out or treatment started?  Yes  No  
 TB Test:  Positive  Negative Date: \_\_\_\_\_

#### Prior Failed Treatments:

5-ASA \_\_\_\_\_  
 Biologics \_\_\_\_\_  
 Corticosteroids \_\_\_\_\_  
 Immunosuppressants \_\_\_\_\_  
 Methotrexate \_\_\_\_\_  
 Surgery \_\_\_\_\_  
 Other \_\_\_\_\_

#### Indicate Drug Name and Length of Treatment:

#### If Prior Authorization is Denied:

Automatically Draft Appeal for Review  
 Send Preferred Formulary Alternatives

### 4 PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> CIMZIA®	<input type="checkbox"/> Prefilled Syringe Starter Kit	<input type="checkbox"/> <b>Induction Dose:</b> Inject 400mg SC on day 1, 14 and 28	6	0
	<input type="checkbox"/> 200mg/ml Prefilled Syringe	<input type="checkbox"/> <b>Maintenance:</b> Inject 400mg SC every 4 weeks	2	
	<input type="checkbox"/> 200mg Lyophilized Powder	<input type="checkbox"/> _____		
<input type="checkbox"/> HUMIRA®	<input type="checkbox"/> Crohn's Disease/ Ulcerative Colitis Starter Kit	<input type="checkbox"/> <b>Induction Dose:</b> Inject 160mg SC on day 1, then 80mg SC on day 15, then switch to maintenance dose	6	0
	<input type="checkbox"/> 40mg/0.8ml Pen	<input type="checkbox"/> <b>Maintenance:</b> Inject 40mg SC every other week	2	
	<input type="checkbox"/> 40mg/0.8ml Prefilled Syringe	<input type="checkbox"/> _____ <input type="checkbox"/> Patient has signed HUMIRA Complete form		
<input type="checkbox"/> SIMPONI®	<input type="checkbox"/> 100mg/ml Smartject® Autoinjector	<input type="checkbox"/> <b>Induction Dose:</b> Inject 200mg SC at week 0, 100mg SC at week 2 and then switch to maintenance dose	3	0
	<input type="checkbox"/> 100mg/ml Prefilled Syringe	<input type="checkbox"/> <b>Maintenance:</b> Inject 100mg SC every 4 weeks	1	
<input type="checkbox"/> STELARA®	<input type="checkbox"/> 130mg/26ml Vial	<input type="checkbox"/> <b>Induction Dose:</b> Patient Weight <55kg: 260mg; >55kg to 85kg: 390mg; >85 kg: 520mg administered IV		0
	<input type="checkbox"/> 45mg/0.5ml Prefilled Syringe	<input type="checkbox"/> <b>Maintenance Dose:</b> Inject 90mg SC 8 weeks after the initial intravenous dose, then every 8 weeks thereafter	1	
	<input type="checkbox"/> 90mg/ml Prefilled Syringe <input type="checkbox"/> 45mg/0.5ml Vial			
<input type="checkbox"/> UCERIS®	<input type="checkbox"/> 9mg Tablets	<input type="checkbox"/> Take one tablet daily in the morning with or without food	30	1
<input type="checkbox"/> XIFAXAN®	<input type="checkbox"/> 550mg Tablets	<input type="checkbox"/> Take one tablet three times daily for 14 days	42	
<input type="checkbox"/> _____	_____	_____		

### 5 INJECTION TRAINING: Pharmacist to Provide Training Patient Trained in MD Office Manufacturer Nurse Support

### 6 PRODUCT DELIVERY: Patient's Home Physician's Office Pharmacy to Coordinate

### 7 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

### 8 PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Substitution Permitted Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.